NASDAQ:KYTX

Kyverna Therapeutics Q3 2026 Earnings Results & Report

Kyverna Therapeutics logo
$4.37 -0.11 (-2.46%)
As of 02:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kyverna Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.68 versus the -$0.6913 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Kyverna Therapeutics EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.6913
Beat/Miss
Beat by +$0.0113
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Kyverna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kyverna Therapeutics Q3 2026 Earnings FAQ

Kyverna Therapeutics (NASDAQ:KYTX) reported earnings of -$0.68 per share for Q3 2026, beating the consensus estimate of -$0.6913. The report was announced on Thursday, November 12, 2026.

Kyverna Therapeutics Earnings Headlines

HC Wainwright Has Bearish Estimate for KYTX FY2026 Earnings
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Kyverna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email.

About Kyverna Therapeutics

Kyverna Therapeutics (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells.

Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.

Founded in 2018 and based in Emeryville, California, Kyverna is focused on advancing its cell therapy candidates through clinical development.

View Kyverna Therapeutics Profile